BMS completes Phase 3 trial of nivolumab and leratorimab for colorectal cancer
Colorectal cancer: © Peterschreiber.media – Stock.adobe.com Bristol-Myers Squibb is conducting a Phase 3 RELATIVITY study investigating nivolumab (Opdivo) and relatlimab (Opdualag) in patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer (CRC). -123 study (NCT05328908) has been completed and will not progress beyond 1. It is more effective than 4-line treatment because it is […]
Oncolytics Biotech Inc. Announces Anal Cancer Cohort of Peraleolep and Atezolizumab Goblet Phase 1/2 Clinical Trial Meets Efficacy Criteria – November 9, 2023, 7:01 a.m. EST
Oncolytics Biotech Inc. announces positive interim results from the Phase 1/2 GOBLET trial evaluating the combination of perolep and atezolizumab in second-line patients with unresectable anal canal squamous cell carcinoma, led by Dirk Arnold, MD. It was announced that it was announced. Director of the Asklepios Oncology Center in Hamburg and principal investigator of the […]
Oncolytics Announces Anal Cancer Cohort of GOBLET Phase 1/2 Study of Peralolep and Atezolizumab Meets Efficacy Success Criteria
Data for the combination of peralolep and atezolizumab exceeds previous controlled trials with an objective response rate of 37.5%, including complete responses. SAN DIEGO and CALGARY, Alberta, Nov. 9, 2023 /PRNewswire/ — Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), an oncology-focused clinical-stage immunotherapy company, today announced that gave a presentation on intermediate therapeutic drugs. Results […]
Motixafortide shows efficacy as primary treatment for pancreatic cancer in phase 2 trial
Pancreas image | Image credit: © Лилия Захарчук – Stock.adobe.com Motixafortide, a CXC4 inhibitor, when combined with the PD-1 inhibitor cemiplimab and the standard of care (SoC) chemotherapy treatment gemcitabine and nab-paclitaxel (MCGN) Phase 2 Data from the CheMo4METPANC trial (NCT04543071) showed some positive results against (mPDAC). This data, presented as an abstract as part […]